[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342836-105":59,"doc-detail-342836-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","editorial-targeting-key-cellular-signaling-network-for-cancer-chemotherapy-and-immunotherapy","Editorial - Targeting key cellular signaling network for cancer chemotherapy and immunotherapy","","Editorial on the research topic of targeting key cellular signaling networks in cancer chemotherapy and immunotherapy. The text emphasizes how signaling pathways governing cell growth, proliferation, and apoptosis become dysregulated in tumors, highlighting major pathways such as PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and JAK/STAT. It contrasts conventional chemotherapy with targeted therapy and immunotherapy, including checkpoint inhibitors and CAR T cells, and summarizes related progress in multiple cancer types. ",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/editorial-targeting-key-cellular-signaling-network-for-cancer-chemotherapy-and-immunotherapy/342836/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/editorial-targeting-key-cellular-signaling-network-for-cancer-chemotherapy-and-immunotherapy/342836.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main focus of this editorial?","Question",{"text":113,"@type":114},"It focuses on the research progress and functions of key cellular signaling networks in tumor chemotherapy and immunotherapy, aiming to clarify regulatory mechanisms that may support new targeted and chemotherapy drug development.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which signaling pathways are highlighted as frequently disrupted in cancer?",{"text":118,"@type":114},"The editorial highlights PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and JAK/STAT pathways as pathways often disrupted in cancer cells.",{"name":120,"@type":111,"acceptedAnswer":121},"How does immunotherapy differ from traditional chemotherapy in the text?",{"text":122,"@type":114},"The editorial explains that traditional chemotherapy broadly targets rapidly dividing cells, while immunotherapy leverages the body’s immune system, using approaches such as immune checkpoint inhibitors and CAR T-cell therapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},342836,1790160473,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":24,"preview_page_count":14,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","TYPE Editorial  \nPUBLISHED 13 May 2024  \nDOI 10.3389/fimmu.2024.1423917  \nOPEN ACCESS  \nEDITED AND REVIEWED BY Peter Brossart,  \nUniversity of Bonn, Germany  \n*CORRESPONDENCE Zhendong Jin  \n [zhendongjin@163.com](zhendongjin@163.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 26 April 2024  \nACCEPTED 03 May 2024  \nPUBLISHED 13 May 2024  \nCITATION  \nLi W, Wang X, Wan D, Li J and Jin Z (2024) Editorial: Targeting key cellular signaling network for cancer chemotherapy and immunotherapy.  \nFront. Immunol. 15:1423917 .  \ndoi: 10.3389/fimmu.2024.1423917  \nCOPYRIGHT  \n© 2024 Li, Wang, Wan, Li and Jin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nEditorial: Targeting key cellular signaling network for cancer chemotherapy and immunotherapy  \nWanshun Li 1,2†, Xinyue Wang 1†, Dongling Wan 1†, Jiayu Li 1,2 and Zhendong Jin 1*  \n1 Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, China, 2College of Basic Medical Science, Naval Medical University, Shanghai, China  \nKEYWORDS  \ncellular signaling network, chemotherapy, Immunotherapy, Cancer, targeted therapy  \nEditorial on the Research Topic  \nTargeting key cellular signaling network for cancer chemotherapy and immunotherapy  \nIn the dynamic ﬁeld of oncology, the strategic targeting of cellular signaling networks marks a transformative approach in cancer treatment, speciﬁcally through chemotherapy and immunotherapy. This focus is based on the premise that understanding and manipulating the intricate signaling pathways that regulate cell growth, proliferation, and death can lead to more effective and less toxic treatment modalities (1, 2) . This Research Topic focuses on the research progress of key signal networks in tumor chemotherapy and immunotherapy, with the aim of comprehensively and deeply elucidating the functions and regulatory mechanisms of key signal networks in the process of tumor cell proliferation, metastasis and drug resistance, and contributing to the development of new chemotherapy drugs and targeted therapies.  \nCellular signaling networks encompass various pathways that regulate essential cellular activities such as growth, apoptosis, and differentiation. In cancer, these pathways often become aberrant, leading to uncontrolled cell division and tumor progression. Key pathways such as the PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and JAK/STAT pathways are frequently disrupted in cancerous cells (3) . By speciﬁcally targeting these pathways, treatments can directly hinder the growth of cancer cells and potentially lead to more successful outcomes. Zhang et al. analyzed the complex molecular terrain of thymic epithelial tumors and important key genes and signaling pathways in tumorigenesis in order to highlight the signiﬁcant inﬂuence of tumor microenvironment on tumor behavior and treatment response.  \nThe traditional approach of chemotherapy, which indiscriminately targets rapidly dividing cells, is being supplemented and sometimes replaced by targeted therapies and immunotherapies. Targeted therapies focus on speciﬁc components within signaling pathways, thereby minimizing damage to normal cells and reducing side effects. Immunotherapy, on the other hand, leverages the body’s immune system to ﬁght cancer, utilizing methods like immune checkpoint inhibitors and CAR T-cell therapy (4) . These  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nmethods have transformed treatment paradigms, particularly for cancers that were previously deemed untreatable with conventional approaches. Huang","cbCaif516e3oensq","https://ap.wps.com/l/cbCaif516e3oensq","pdf",254318,"English","# Editorial on the Research Topic\n## Targeting cellular signaling networks in cancer treatment\n## Key signaling pathways and therapeutic targeting\n## Chemotherapy, targeted therapy, and immunotherapy integration","[{\"question\":\"What is the main focus of this editorial?\",\"answer\":\"It focuses on the research progress and functions of key cellular signaling networks in tumor chemotherapy and immunotherapy, aiming to clarify regulatory mechanisms that may support new targeted and chemotherapy drug development.\"},{\"question\":\"Which signaling pathways are highlighted as frequently disrupted in cancer?\",\"answer\":\"The editorial highlights PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and JAK/STAT pathways as pathways often disrupted in cancer cells.\"},{\"question\":\"How does immunotherapy differ from traditional chemotherapy in the text?\",\"answer\":\"The editorial explains that traditional chemotherapy broadly targets rapidly dividing cells, while immunotherapy leverages the body’s immune system, using approaches such as immune checkpoint inhibitors and CAR T-cell therapy.\"}]","Editorial - Targeting key cellular signaling network for cancer chemotherapy and immunotherapy | PDF",1790048371,[146,150],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ea0e92504ecb6cd4ffdd9ef553192c3.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a5b81e11fab78261bea6dea34060203.webp",982,1388]